SAB Biotherapeutics, Inc. (SABS) announced on Tuesday that the FDA has granted clearance for an investigational new drug application to advance its phase 1 clinical trial of SAB-142 for treating type-1 diabetes.
Phase 1 trial of SAB-142 involves a human trial, to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and pharmacodynamic profile of the human anti-thymocyte biologic SAB-142 in healthy volunteers and patients with type-1 diabetes.
The study follows a randomized, double-blind, single-ascending dose trial design, with dosages ranging from .03mg/kg to 2.5mg/kg, a range similar to that explored in the MELD-ATG study, a dose-ranging rabbit ATG study in individuals with new-onset T1D.
The company stated that similar to rabbit ATG, SAB-142 specifically targets various immune cells responsible for destroying pancreatic beta cells, but without the potential risk of triggering significant adverse immune reactions associated with animal ATG administration.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.